Single cell cloning (SCC) and associated cloning efficiency (colony outgrowth) for mammalian cells is currently regarded as an important and discrete step in many applications from cell engineering; antibody discovery; monoclonal antibody production; to vaccine production and many more.
The degree of importance placed upon achieving a clonally derived cell line can vary greatly between applications from regulatory requirements to target validation for a disease model. However, the importance is still paramount to the application.
Currently, for many laboratories, flow cytometry (FACS) or limiting dilution (LD) is the current method of choice for single cell deposition. However, each method has its drawbacks.
When using FACS, very high seeding efficiency results can be achieved but often at the
expense of cell survival and growth due to the harsh treatment of the cells during processing. When using LD, the reverse is the case; good cell survival can be
achieved, but at low seeding efficiencies.
These intrinsic inefficiencies often result in a combination of the two processes being implemented and used on a case by case basis; FACS for robust cell lines and LD for sensitive cell lines. In addition to these drawbacks, neither of these processes offers independent confirmation of the single cell deposition and hence a separate whole well imaging step is required.
During this presentation, we introduce the world’s first integrated and dedicated SCC platform called Verified In-Situ Plate Seeding (or VIPS™). VIPS combines gentle single cell deposition with concurrent in-situ image verification of the single cell in a well, all in one instrument, for the purpose of providing the user with increased process efficiency and immediate high confidence confirmation of clonality.
We will outline the workings of the VIPS system, discuss the features and benefits that make the workflow process superior and will highlight the points which make the system unique compared with competitive technologies.
This presentation will show that VIPS should be an essential part of any major academic or industrial lab which is developing or manipulating a cell line that needs efficient single cell cloning tied with higher confidence in clonality.
Dr Ian Taylor,
Commercial Director
Dr Taylor has a PhD in Biochemistry. He has more than 25 years working in the conceptualisation and commercialisation of novel high value life-science instrumentation.
Prior to joining Solentim when it was founded nearly 8 years ago, Dr Taylor was Commercial Director at Genetix PLC where he was responsible for the development and sales of the ClonePix FL for selection and isolation of high value mAb producing clones.
Prior to that, Dr Taylor was part of the leadership team for PerkinElmer Life Sciences.
Dr Erika Parkinson,
Head of R&D Biology
After receiving her PhD in the field of Proteomics from Nottingham Trent University in 2006, Erika took a Research Fellow position, followed by a Senior Research Fellow position, within the Centre for Proteomic Research at Southampton University.
During this time Erika used mammalian (including human) primary and immortal cell lines and 3D skin models to study the effect of protein haptenation in the elicitation of skin allergy in collaboration with Unilever plc.
After 11 years in academia, Erika joined Solentim to head the Biology Department and to run the Cell Culture Facility.
- Multiple elements that impact efficiency of clonality all of which can be controlled
- Improvements over conventional methods of FACS and LD
- Practical benefits of seeding and imaging of a single cell in an arrayed droplet
- Head of Departments
- Scientific Directors
- VPs of R&D
- CMC Directors
- Senior Scientist
- Research Scientists I
- Research Scientists II
- Research Scientists III
- Principal Scientists
- Team Leaders
- Research Associates
- Associate Scientists
- Senior Associate Scientists
- Group Leaders
